ASH 2020

HEOR | Peripheral T-Cell Lymphoma | Abstract 1606

Economic Assessment of Diagnostic Revision in Peripheral T-Cell Lymphoma

Brentuximab vedotin | Peripheral T-Cell Lymphoma | Abstract 1150

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

HEOR | Classical Hodgkin Lymphhoma | Abstract 2499

Real-World Characteristics of Patients with Classical Hodgkin Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching

HEOR | Classical Hodgkin Lymphoma| Abstract 2033

Real-world Adherence to National Comprehensive Cancer Network (NCCN) Guidelines Regarding the Usage of PET/CT and Reported Deauville Scores in Advanced Stage Classical Hodgkin Lymphoma: A Community Oncology Practice Perspective

Brentuximab vedotin | Mediastinal Gray Zone Lymphoma | Abstract 2045

Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Mediastinal Gray Zone Lymphoma: Primary Efficacy and Safety Analysis of the Phase 2 CheckMate 436 Study

Brentuximab vedotin | Hodgkin Lymphoma | Abstract 471

Frontline Brentuximab Vedotin as Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

HEOR | Peripheral T-Cell Lymphoma | Abstract 3418

Real-World Characteristics of Patients with Peripheral T-Cell Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching

SEA-CD70 | Myeloid Malignancies | Abstract 2874

A Phase 1 Study of SEA-CD70 in Myeloid Malignancies

Brentuximab vedotin | Classical Hodgkin Lymphoma | Abstract 2973

Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study

Brentuximab vedotin | Peripheral T-Cell Lymphoma | Abstract 2976

Trial-in-Progress: Frontline Brentuximab Vedotin and CHP (A+CHP) in Patients with Peripheral T-Cell Lymphoma with Less Than 10% CD30 Expression